Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that improved patient and physician awareness resulting from direct-to-consumer advertising and the use of more costly long- acting agents will grow the market for the treatment of urge urinary incontinence (UUI).

"Although UUI affects nearly 46 million people in the seven major pharmaceutical markets in our study (United States, France, Germany, Italy, Spain, United Kingdom, and Japan), patients have not generally sought medical attention for the problem," said Dancella Fernandes, Ph.D., analyst at Decision Resources, Inc. "Although patient and clinician awareness of UUI and its treatment has been on the rise in recent years, a majority of UUI patients remains undiagnosed."

The new Pharmacor report, entitled Urge Urinary Incontinence also finds that a new generation of anticholinergics from Astellas Pharma and Novartis offer improved efficacy or side-effect-profiles with less-frequent dosing. The attributes stand to improve patient compliance and persistence with UUI therapies and help counteract the typically high discontinuation rate for anticholinergics.

About Urge Urinary Incontinence (UUI)

The market for urge urinary incontinence (UUI), the involuntary loss of urine accompanied by a strong and sudden urge to void, poses a social, hygienic, and economic hardship and is characterized by very low patient presentation rates (and therefore low diagnosis rates). Improved awareness, as well as the availability of long-acting, selective agents with improved side-effect profiles, will drive robust market growth over the next ten years.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Most Physicians Plan to Prescribe Sanofi-Aventis's Acomplia for Obesity Following the Drug's Anticipated Launch in 2006

View Now